A new study published in Endocrine Connections highlights the adverse effects of cardiovascular disease (CVD) on patients hospitalized with diabetic ketoacidosis (DKA). As found in the national hospitalization data from 2016 to 2022, researchers found that CVD is not just a comorbidity but a critical factor that significantly worsens patient outcomes.

The analysis revealed that 16.8% of hospitalized DKA patients also had CVD. Most importantly, these individuals faced a fivefold increase in in-hospital mortality (1.6% vs. 0.3%). Arrhythmias carried the highest risk, with an adjusted odds ratio exceeding 70 for mortality. Other conditions such as pulmonary hypertension and cardiomyopathy, also contributed to poor outcomes.

Beyond survival, patients with both DKA and CVD experienced longer hospital stays and nearly $13,000 more in healthcare costs compared to those without CVD. Complications, including respiratory failure, septic shock, and thromboembolic events, were also significantly higher in this group.

The findings highlight the importance of early identification of cardiovascular comorbidities in DKA admissions. The role of preventive glycemic management in patients with known CVD is also an important factor. Researchers suggest that multidisciplinary care pathways and closer cardiac monitoring could reduce complications and improve survival.

As the diabetes population continues to grow, there is an urgent need for tailored interventions to mitigate the dual burden of metabolic and cardiovascular disease in high-risk patients.